Theacrine as a Potential Caffeine Alternative for Enhanced Ergogenic and Cognitive Performance in Athletes: A Call to Action and Brief Review
Journal of Exercise and Nutrition · 2021
DOI: 10.53520/jen2021.10397 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Exercise and Nutrition, 2021. Verfasst von Harris Dillon und 1 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Theacrine supplementation has begun recent investigation aimed to increase athletic performance. Although existing literature has examined theacrine’s potential to increase physical and cognitive performance via adenosine receptor inhibition alongside its promotion of overall health and slight cognitive enhancement. Therefore, theacrine ostensibly exists as a caffeine substitute for attenuating both physical and mental fatigue. This article aims to (a) demonstrate the structural/mechanistic similarities of caffeine & theacrine, (b) showcase their existing performance roles, and (c) establish the need for future investigations on theacrine as a potential ergogenic aid in physically active populations to both prophylactically prevent fatigue and augment performance.
Zitieren
APA
Dillon, H., & Steven, M. (2021). Theacrine as a Potential Caffeine Alternative for Enhanced Ergogenic and Cognitive Performance in Athletes: A Call to Action and Brief Review. Journal of Exercise and Nutrition. https://doi.org/10.53520/jen2021.10397
Vancouver
Dillon H, Steven M. Theacrine as a Potential Caffeine Alternative for Enhanced Ergogenic and Cognitive Performance in Athletes: A Call to Action and Brief Review. Journal of Exercise and Nutrition. 2021. doi:10.53520/jen2021.10397
BibTeX
@article{Dillon2021,
author = {Dillon, Harris and Steven, Machek},
title = {Theacrine as a Potential Caffeine Alternative for Enhanced Ergogenic and Cognitive Performance in Athletes: A Call to Action and Brief Review},
journal = {Journal of Exercise and Nutrition},
year = {2021},
doi = {10.53520/jen2021.10397}
}
EUVIMED